A new flu vaccine geared to older people is coming soon
The FDA has approved Moderna's mRNA-based flu vaccine, mFLUSIVA, for individuals aged 50 and older. The vaccine is expected to be available for the 2026-2027 respiratory season, marking a significant milestone for mRNA technology despite political opposition.
Why it matters
This approval represents a major shift in vaccine technology for seasonal illnesses, though it faces scrutiny due to the current administration's skepticism toward mRNA platforms.
For the latest stories on the science of healthy living, subscribe to NPR's Health newsletter .
The Food and Drug Administration approved Moderna's mRNA-based vaccine against seasonal influenza for people 50 and older, the company said late Wednesday .
It's the first approved vaccine for flu that uses the same technology as COVID-19 shots.
Health FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned The vaccine is called mFLUSIVA, and Moderna says it will be available "in a few weeks" — in time for the 2026-2027 respiratory virus season in the U.S.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in